Address
2000 Frontis Plaza Blvd.
Winston-Salem, NC 27103
United States of America (the)
Phone
336 999 7028
Website
Sector
Healthcare
Industry
Biotechnology
Employees
204
First IPO Date
June 30, 2021
| Name | Title | Pay | Year Born |
| Bruce Culleton | Chief Executive Officer & Director | 1.18M | 1969 |
| Ulrich Ernst | EVice President of Science and Technology | 622,743 | 1962 |
| James Coulston | Chief Financial Officer | 724,872 | 1977 |
| Todd C. Girolamo | Chief Legal Officer & Secretary | 725,102 | 1965 |
| Kenneth Locke | Chief Technical Officer | 0 | N/A |
| Darin J. Weber | Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access | 0 | 1968 |
| Carla Poulson | Chief People Officer | 0 | N/A |
| Emily Butler | Senior Vice President of Biometric | 0 | N/A |
| Joseph Stavas | SVP of Clinical Affairs | 0 | N/A |
| Gregory Madison | Chief Commercial Officer | 0 | 1967 |
| Richard Williams | Chief Information Officer | 0 | N/A |
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.